Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 18 of 18 results for fingolimod

  1. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

    NICE guideline
    Published
    22 June 2022
    View recommendations

    Sections for NG220

  2. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

    Medtech innovation briefing
    Published
    29 March 2022

  3. Siponimod for treating secondary progressive multiple sclerosis (TA656)

    Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    18 November 2020
    View recommendations

    Sections for TA656